Related Experiment Videos
[Stomach diseases].
C Nichita1, F Viani, F Vouillamoz
1Service de Gastro-entérologie et d'Hépatologie, CHUV, 1011 Lausanne.
Revue Medicale Suisse
|February 24, 2006
Summary
New proton pump inhibitors (PPIs) show faster, longer effectiveness for reflux disease. Endoscopic treatments are declining, and COX-2 inhibitors face reduced use due to cardiac risks.
Area of Science:
- Gastroenterology
- Pharmacology
Context:
- Reflux disease treatment is shifting away from endoscopic procedures.
- Concerns regarding cardiac side effects have limited the use of COX-2 inhibitors.
- High-risk patients for NSAID gastro-duodenal toxicity require alternative management strategies.
Purpose:
- To review current trends in gastrointestinal pharmacotherapy.
- To highlight advancements in proton pump inhibitor (PPI) development.
- To discuss the evolving landscape of treatments for reflux disease and NSAID-induced complications.
Summary:
- A new generation of PPIs with rapid and sustained action is in clinical trials for reflux disease.
- The efficacy and safety profile of PPIs make them a preferred option over declining endoscopic treatments.
- For patients at risk of NSAID-induced gastro-duodenal toxicity, non-specific NSAIDs combined with PPIs remain a viable therapeutic approach.
- High-dose antibiotics are increasingly favored for second-line Helicobacter pylori eradication.
Impact:
- These advancements offer improved therapeutic options for patients with acid-related disorders.
- The findings guide clinical practice in managing reflux disease and NSAID-related risks.
- Future research will likely focus on optimizing PPI efficacy and safety, alongside antibiotic stewardship in H. pylori treatment.